Screener / SEC EDGAR /CIK 0000882796 /10-K filed Feb 26, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Biocryst Pharmaceuticals Inc BCRX

Compare with peers Embed
FY2025 at a glance

Sales up 94.1%, free cash flow up to $344.9M

XBRL, from each 10-K
RevenueStatements
$874.8M from $450.7M in FY2024
FY2016FY2025
Net incomeStatements
$263.9M from -$88.9M in FY2024
FY2016FY2025
Free cash flowStatements
$344.9M from -$53.1M in FY2024
FY2016FY2025
EPS (diluted)Statements
$1.21 from $-0.43 in FY2024
FY2016FY2025
Operating marginStatements
39.0% from -0.6% in FY2024
FY2016FY2025
Total debtStatements
$0 from $314.9M in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (39)
EPS (ttm)
-1.28
Sales (ttm)
961.5M
Net income (ttm)
-359.7M
Sales growth
+94.1%
EPS growth
-
Sales Q/Q
+13.1%
Free cash flow
365.8M
Gross margin
97.8%
Oper. margin
-30.1%
Net margin
-37.4%
FCF margin
38.0%
ROE
n/m
R&D / sales
19.0%
Dividend
-
Debt/Eq
n/m
Curr. ratio
2.71
Cash
97.0M
Op. cash flow (ttm)
367.5M
EBITDA
342.4M
EBITDA margin
39.1%
Net debt
298.6M
Quick ratio
2.68
Interest cover
4.32
FCF after stock pay
259.8M
Debt / FCF (years)
1.15
Oper. margin low 5y
-113.1%
Tax rate
1.3%
Stock pay / sales
9.7%
Shares out.
257.3M
Shares Y/Y
+5.7%
Book / share
-1.54
Cash / share
0.38
Sales / share
3.74
Asset turnover
1.63
Inventory turns
3.53
Days sales out.
45
Sales 3Y CAGR
+47.8%
Sales 5Y CAGR
+118%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 874.8M +47.6% a year Net income 263.9M
FY2016 revenue 26.4M · Revenues, 0001171843-18-001855 FY2016 net income -55.1M · NetIncomeLoss, 0001171843-19-001727 26.4M FY2016 FY2017 revenue 25.2M · Revenues, 0001171843-18-001855 FY2017 net income -65.8M · NetIncomeLoss, 0001171843-20-001710 25.2M FY2017 FY2018 revenue 20.7M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001171843-21-001411 FY2018 net income -101.3M · NetIncomeLoss, 0001171843-21-001411 20.7M FY2018 FY2019 revenue 48.8M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001171843-22-001460 FY2019 net income -108.9M · NetIncomeLoss, 0001171843-22-001460 48.8M FY2019 FY2020 revenue 17.8M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001628280-23-005259 FY2020 net income -182.8M · NetIncomeLoss, 0001628280-23-005259 17.8M FY2020 FY2021 revenue 157.2M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001628280-24-007205 FY2021 net income -184.1M · NetIncomeLoss, 0001628280-24-007205 157.2M FY2021 FY2022 revenue 270.8M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001628280-25-007715 FY2022 net income -247.1M · NetIncomeLoss, 0001628280-25-007715 270.8M FY2022 FY2023 revenue 331.4M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001628280-26-012240 FY2023 net income -226.5M · NetIncomeLoss, 0001628280-26-012240 331.4M FY2023 FY2024 revenue 450.7M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001628280-26-012240 FY2024 net income -88.9M · NetIncomeLoss, 0001628280-26-012240 450.7M FY2024 FY2025 revenue 874.8M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001628280-26-012240 FY2025 net income 263.9M · NetIncomeLoss, 0001628280-26-012240 874.8M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $404.3M
  • − All liabilities $633.3M
  • = Net current asset value -$229.0M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $119.2M
  • = Tangible book value -$119.2M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

BCRX against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+94.1%8th of 155 · median +10.5%
Net margin
-4.1%15.3%
-37.4%134th of 154 · median 6.8%
Free cash flow margin
2.3%19.2%
38.0%5th of 145 · median 10.0%
BCRX and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
BCRX Biocryst Pharmaceuticals Inc$961.5M +94.1%97.8%-37.4%-38.0%-
CORT Corcept Therapeutics Inc$963.6M +12.8%-16.8%19.5%20.2%-
IONS Ionis Pharmaceuticals Inc$960.1M +33.8%--56.9%-138.8%-64.2%4.60
BBIO BridgeBio Pharma, Inc.$945.5M +126%94.3%-62.6%--39.1%-
WRBY Warby Parker Inc.$934.7M +13.0%54.7%0.8%1.9%2.3%-
TGTX TG Therapeutics, Inc.$897.8M +87.3%82.7%11.8%18.5%9.5%1.30
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement

From $874.8M of sales to $263.9M of profit FY2025

Revenue to Gross profit: $855.8MRevenue to Cost of revenue: $19.1MGross profit to Operating profit: $341.0MGross profit to Operating expenses: $514.8MOperating profit to Net profit: $263.9MOperating profit to Tax & other: $77.1MOperating expenses to R&D: $166.1MOperating expenses to SG&A: $348.6M Revenue: $874.8M REVENUE $874.8M +94% Y/Y Gross profit: $855.8M · 98% margin GROSS PROFIT $855.8M 98% margin Cost of revenue: $19.1M · 2% of revenue COST OF REVENUE $19.1M 2% of revenue Operating profit: $341.0M · 39% margin OPERATING PROFIT $341.0M 39% margin Operating expenses: $514.8M · 59% of revenue OPERATING EXPENSES $514.8M 59% of revenue Net profit: $263.9M · 30% margin NET PROFIT $263.9M 30% margin Tax & other: $77.1M · 9% of revenue TAX & OTHER $77.1M 9% of revenue R&D: $166.1M · 19% of revenue R&D $166.1M 19% of revenue SG&A: $348.6M · 40% of revenue SG&A $348.6M 40% of revenue

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. The full income statement

Profitability

  • Net margin below the peer median
    -37.4% vs 6.8%
  • A profit in 1 of 10 years
Net margin, FY2016 to FY2025: -209.3% to 30.2%

Balance sheet

  • Interest covered less than 5 times
    Operating income is 4.3× interest expense
  • Equity below zero
    Debt $395.6M, equity −$397.4M
  • Current assets cover current liabilities
    Current ratio 2.71
  • Net debt under 3 years of free cash flow
    $113.6M net debt, 0.3 years
Debt / equity at each year end, FY2016 to FY2025: 14.58 to 1.31

Cash and shareholders

  • Free cash flow positive in 1 of 10 years
    $344.9M last year
  • Share count up over 5 years
    +30.7%
  • Cash from operations above net income
    $347.4M vs $263.9M
Free cash flow, FY2016 to FY2025: -58.7M to 344.9M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities

Paid in advance $22.1M cash received before delivery, not yet recognized as revenue, Sep 30, 2026

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

BCRX's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue874.8M
FY2016: 26.4MFY2017: 25.2MFY2018: 20.7MFY2019: 48.8MFY2020: 17.8MFY2021: 157.2MFY2022: 270.8MFY2023: 331.4MFY2024: 450.7MFY2025: 874.8M FY2017FY2019FY2021FY2023FY2025
Net income263.9M
FY2016: -55.1MFY2017: -65.8MFY2018: -101.3MFY2019: -108.9MFY2020: -182.8MFY2021: -184.1MFY2022: -247.1MFY2023: -226.5MFY2024: -88.9MFY2025: 263.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow344.9M
FY2016: -58.7MFY2017: -41.5MFY2018: -92.9MFY2019: -89.9MFY2020: -135.6MFY2021: -144.5MFY2022: -163.2MFY2023: -97.3MFY2024: -53.1MFY2025: 344.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay259.8M
FY2016: -67.2MFY2017: -54.1MFY2018: -102.3MFY2019: -107.6MFY2020: -150.4MFY2021: -179.2MFY2022: -207.9MFY2023: -152.9MFY2024: -118.6MFY2025: 259.8M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)1.21
FY2016: -0.75FY2017: -0.78FY2018: -0.98FY2019: -940.00FY2020: -1.09FY2021: -1.03FY2022: -1.33FY2023: -1.18FY2024: -0.43FY2025: 1.21 FY2017FY2019FY2021FY2023FY2025
Diluted shares218.6M
FY2016: 73.7MFY2017: 84.5MFY2018: 103.2MFY2019: 115.6MFY2020: 167.3MFY2021: 179.1MFY2022: 185.9MFY2023: 192.2MFY2024: 206.7MFY2025: 218.6M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Total ORLADEYO 601.8M68.8% +37.5%
License and other revenues 251.7M28.8% +3029%
License revenue 244.0M27.9% -
Other revenues 29.0M3.3% +122%
Collaborative and other revenues 7.7M0.9% -4.2%

10-K 0001628280-26-012240, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue26.4M25.2M20.7M48.8M17.8M157.2M270.8M331.4M450.7M874.8M
Cost of revenue2.3M1.1M-3.7M1.6M7.2M6.4M4.5M12.3M19.1M
R&D61.0M67.0M84.9M107.1M123.0M208.8M253.3M216.6M174.6M166.1M
SG&A11.3M13.9M29.5M37.1M67.9M118.8M159.4M214.1M266.3M348.6M
Operating income-48.6M-57.4M-94.2M-99.5M-174.8M-177.7M-148.4M-103.7M-2.5M341.0M
Interest expense6.5M8.6M9.2M11.9M14.5M59.3M99.1M108.2M98.5M78.9M
Pretax income----108.9M-182.8M-181.8M-244.4M-226.2M-87.0M267.4M
Income tax000002.3M2.7M310K1.9M3.5M
Net income-55.1M-65.8M-101.3M-108.9M-182.8M-184.1M-247.1M-226.5M-88.9M263.9M
EPS (diluted)-0.75-0.78-0.98-940.00-1.09-1.03-1.33-1.18-0.431.21
Diluted shares73.7M84.5M103.2M115.6M167.3M179.1M185.9M192.2M206.7M218.6M
Depreciation & amortization483K704K770K724K748K777K1.4M1.7M1.2M1.4M
EBITDA-48.1M-56.7M-93.5M-98.7M-174.0M-176.9M-147.0M-102.1M-1.3M342.4M
Operating margin-184.4%-227.9%-456.2%-203.7%-981.1%-113.1%-54.8%-31.3%-0.6%39.0%
Net margin-209.3%-261.2%-490.3%-223.0%-1026.4%-117.1%-91.2%-68.4%-19.7%30.2%
Revenue growth-45.4%-4.4%-18.0%+136%-63.5%+782%+72.3%+22.4%+36.0%+94.1%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-53.4M-41.1M-92.6M-89.6M-135.1M-142.2M-161.8M-95.1M-52.0M347.4M
Capital spending5.3M328K366K343K514K2.4M1.4M2.2M1.1M2.5M
Free cash flow-58.7M-41.5M-92.9M-89.9M-135.6M-144.5M-163.2M-97.3M-53.1M344.9M
Stock-based pay (added back)8.5M12.6M9.4M17.7M14.8M34.6M44.7M55.6M65.4M85.1M
Free cash flow after stock pay-67.2M-54.1M-102.3M-107.6M-150.4M-179.2M-207.9M-152.9M-118.6M259.8M
Debt raised-----073.1M300.0M00
Debt repaid-------240.5M0300.0M
Investing cash flow23.3M-64.6M4.8M77.9M-6.9M15.8M-128.2M-131.5M52.6M-13.7M
Financing cash flow23.3M135.7M62.5M99.1M300.6M359.7M88.0M32.5M-5.8M-349.9M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)8.5M12.6M9.4M17.7M14.8M34.6M44.7M55.6M65.4M85.1M
Stock-based pay / revenue32.2%50.1%45.5%36.3%83.1%22.0%16.5%16.8%14.5%9.7%
Operating lease cash paid---1.5M1.7M1.5M1.6M1.9M2.2M1.5M
Finance lease principal paid-----001.2M1.7M2.0M
Right-of-use assets-----6.5M4.2M8.7M8.1M7.5M
Operating lease liabilities----5.0M7.8M5.5M9.4M8.9M8.9M
Finance lease liabilities------2.6M4.4M4.0M2.8M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.